Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577499 | 1.00 | THRB (0.53) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| Ethylene SCHEMBL6587621 | 0.96 | THRB (0.50) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL8892851 | 0.94 | THRB (0.47) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL8912926 | 0.93 | SMN1; SMN2 (0.47) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL4868550 | 0.88 | BRD4 (0.47) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL1139285 | 0.88 | BRD4 (0.47) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL17014460 | 0.88 | BRD4 (0.47) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL9633492 | 0.85 | SMN1; SMN2 (0.46) | THRBBRD4SMN1; SMN2KMT2ATP53 | |
| SCHEMBL762706 | 0.81 | THRB (0.42) | THRBSMN1; SMN2KMT2A | |
| SCHEMBL24565374 | 0.80 | ALDH1A1 (0.47) | THRBSMN1; SMN2KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0407909-B1 | Process for the preparation of R-(+)-3-oxo cycloalkane carboxylic lower alkyl esters | BOEHRINGER INGELHEIM KG (DE) | 1994-11-02 | — | — | EP | claimed |
| EP-4704839-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4682148-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2026-01-21 | — | — | EP | disclosed |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | ABBVIE INC (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119431384-A | And lactam ring compound and application thereof | 成都赜灵生物医药科技有限公司 | 2025-02-14 | — | — | CN | disclosed |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | ABBVIE INC. (US) | 2025-01-16 | — | — | US | disclosed |
| EP-4474383-A2 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | AbbVie Ireland Unlimited Company (IE) | 2024-12-11 | — | — | EP | disclosed |
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ALPHERABIO LLC | 2024-11-14 | — | — | US | disclosed |
| WO-2024226608-A2 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | AGLAEAPHARMA INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | ABBVIE INC. (US) | 2024-02-13 | — | — | US | disclosed |
| US-5968954-A | EXHIBIT SELECTIVE BINDING AFFINITY FOR 5-HYDROXYTRYPTAMINE RECEPTORS | ADIR ET COMPAGNIE (FR) | 1999-10-19 | — | — | US | disclosed |
| EP-0861837-A1 | 2-Aminoindane derivatives, process for their preparation and pharmaceutical compositions containing them | ADIR ET COMPAGNIE (FR) | 1998-09-02 | — | — | EP | disclosed |
| US-5691351-A | Bis-(Heteroarylmethoxyphenyl)cycloalkyl carboxylates as inhibitors of leukotriene biosynthesis | ABBOTT LABORATORIES (US) | 1997-11-25 | — | — | US | disclosed |
| WO-1997029090-A1 | BIS-(HETEROARYLMETHOXYPHENYL)CYCLOALKYL DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF LEUKOTRIENE BIOSYTHESIS | ABBOTT LABORATORIES (US) | 1997-08-14 | — | — | WO | disclosed |
| US-5639902-A | FOR TREATING PSORIASIS | ADIR ET COMPAGNIE (FR) | 1997-06-17 | — | — | US | disclosed |
| US-5114960-A | Rheumatoid arthritis; antiinflammatory and antishock agents; gastrointestinal and respiratory system disorders | HOFFMANN-LA ROCHE INC. (US) | 1992-05-19 | — | — | US | disclosed |
| WO-1991007378-A1 | CYCLOALKYL-SUBSTITUTED GLUTARAMIDE DIURETIC AGENTS | PFIZER LIMITED (GB) | 1991-05-30 | — | — | WO | disclosed |
| EP-0409273-A2 | Substituted isoxazole and isothiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1991-01-23 | — | — | EP | disclosed |
| EP-0021940-B1 | AMINO DERIVATIVES OF BENZOTHIAZOLE, PROCESS FOR THEIR PREPARATION AND THEIR USE IN THERAPY | LABORATOIRES JACQUES LOGEAIS Société dite: (FR) | 1983-01-19 | — | — | EP | disclosed |
| EP-0021940-A1 | Amino derivatives of benzothiazole, process for their preparation and their use in therapy | LABORATOIRES JACQUES LOGEAIS Société dite: (FR) | 1981-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11897864-B2 | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases | BCL2, BAX, BCL3 | THRB 2261/4885BRD4 304/4885SMN1; SMN2 2670/4885 |
| US-20250019364-A1 | APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES | BCL2, BAX, BCL3 | THRB 2261/4885BRD4 304/4885SMN1; SMN2 2670/4885 |
| US-20250161318-A1 | SOLID DISPERSIONS CONTAINING AN APOPTOSIS-INDUCING AGENT | BCL2, BAX, BCL2L1 | THRB 4672/4885BRD4 2261/4885SMN1; SMN2 318/4885 |
| US-20240374573-A1 | IMIDAZOLE CONTAINING COMPOUNDS, DERIVATIVES THEREFORE, AND USES THEREOF | ADRB2, ADRA2C, ADRA2B | THRB 59/4885BRD4 1119/4885SMN1; SMN2 2675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.